• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
COVID-19 and its implications on the clinico-radiological course of multiple sclerosis: A case-control study.新型冠状病毒肺炎及其对多发性硬化临床-放射学病程的影响:一项病例对照研究。
Med Clin (Barc). 2023 Mar 10;160(5):187-192. doi: 10.1016/j.medcli.2022.06.020. Epub 2022 Aug 10.
2
COVID-19 and its implications on the clinico-radiological course of multiple sclerosis: A case-control study.新型冠状病毒肺炎及其对多发性硬化症临床放射学病程的影响:一项病例对照研究。
Med Clin (Engl Ed). 2023 Mar 10;160(5):187-192. doi: 10.1016/j.medcle.2022.06.021. Epub 2023 Mar 3.
3
Mitoxantrone: a review of its use in multiple sclerosis.米托蒽醌:其在多发性硬化症中的应用综述
CNS Drugs. 2004;18(6):379-96. doi: 10.2165/00023210-200418060-00010.
4
Management of worsening multiple sclerosis with mitoxantrone: a review.米托蒽醌治疗病情进展型多发性硬化症的研究综述
Clin Ther. 2006 Apr;28(4):461-74. doi: 10.1016/j.clinthera.2006.04.013.
5
Intrathecal IgM index correlates with a severe disease course in multiple sclerosis: Clinical and MRI results.鞘内IgM指数与多发性硬化症的严重病程相关:临床和MRI结果
Clin Neurol Neurosurg. 2017 Sep;160:27-29. doi: 10.1016/j.clineuro.2017.05.026. Epub 2017 Jun 1.
6
Slowly expanding lesions relate to persisting black-holes and clinical outcomes in relapse-onset multiple sclerosis.在复发缓解型多发性硬化症中,缓慢扩大的病灶与持续存在的黑洞和临床结局有关。
Neuroimage Clin. 2022;35:103048. doi: 10.1016/j.nicl.2022.103048. Epub 2022 May 16.
7
Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis.干扰素β与醋酸格拉替雷治疗复发缓解型多发性硬化症的对比
Cochrane Database Syst Rev. 2016 Nov 24;11(11):CD009333. doi: 10.1002/14651858.CD009333.pub3.
8
Early onset multiple sclerosis and the effect of disease onset age on neurological disability in multiple sclerosis.早发性多发性硬化症与发病年龄对多发性硬化症神经残疾的影响。
Clin Neurol Neurosurg. 2023 Jan;224:107528. doi: 10.1016/j.clineuro.2022.107528. Epub 2022 Nov 23.
9
Efficacy, safety and patient reported outcomes in patients with active relapsing multiple sclerosis treated with ocrelizumab: Final results from the PRO-MSACTIVE study.奥瑞珠单抗治疗复发型多发性硬化症患者的疗效、安全性及患者报告结局:PRO-MSACTIVE研究的最终结果
Mult Scler Relat Disord. 2022 Dec;68:104109. doi: 10.1016/j.msard.2022.104109. Epub 2022 Aug 13.
10
Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis.残疾与T2加权磁共振成像病变:对复发型多发性硬化症患者的20年随访
Brain. 2008 Mar;131(Pt 3):808-17. doi: 10.1093/brain/awm329. Epub 2008 Jan 29.

引用本文的文献

1
Incidence of multiple sclerosis (MS) relapse after COVID-19 infection: A systematic review and meta-analysis.新型冠状病毒肺炎(COVID-19)感染后多发性硬化症(MS)复发的发生率:一项系统评价和荟萃分析。
Caspian J Intern Med. 2025 Mar 11;16(2):192-197. doi: 10.22088/cjim.16.2.192. eCollection 2025 Spring.
2
Impact of COVID-19 on long-term outcomes in Parkinson's disease.新冠病毒病对帕金森病长期预后的影响
Eur J Neurol. 2025 May;32(5):e70013. doi: 10.1111/ene.70013.
3
Long-Term Outcomes of Patients with Pre-Existing Essential Tremor After SARS-CoV-2 Infection.新冠病毒感染前已患特发性震颤患者的长期预后
Diagnostics (Basel). 2024 Dec 10;14(24):2774. doi: 10.3390/diagnostics14242774.
4
COVID-19 and multiple sclerosis: challenges and lessons for patient care.2019冠状病毒病与多发性硬化症:患者护理面临的挑战与经验教训
Lancet Reg Health Eur. 2024 Aug 22;44:100979. doi: 10.1016/j.lanepe.2024.100979. eCollection 2024 Sep.
5
COVID-19 Vaccination and Disease Course in People with Multiple Sclerosis in Greece.希腊多发性硬化症患者的新冠疫苗接种与病程
J Clin Med. 2023 Aug 23;12(17):5460. doi: 10.3390/jcm12175460.
6
The Potential Role of SARS-CoV-2 Infection and Vaccines in Multiple Sclerosis Onset and Reactivation: A Case Series and Literature Review.严重急性呼吸综合征冠状病毒 2 感染和疫苗在多发性硬化症发病和再激活中的潜在作用:病例系列和文献复习。
Viruses. 2023 Jul 18;15(7):1569. doi: 10.3390/v15071569.

本文引用的文献

1
Implementing coronavirus disease 2019 scale-up registry protocol in national multiple sclerosis registry system of Iran.在伊朗国家多发性硬化症登记系统中实施2019冠状病毒病扩大登记方案。
Curr J Neurol. 2021 Oct 7;20(4):241-245. doi: 10.18502/cjn.v20i4.8351.
2
Clinical Onset and Multiple Sclerosis Relapse after SARS-CoV-2 Infection.新型冠状病毒2019感染后的临床发病与多发性硬化症复发
Neurol Int. 2021 Dec 6;13(4):695-700. doi: 10.3390/neurolint13040066.
3
Association of CNS demyelination and COVID-19 infection: an updated systematic review.中枢神经系统脱髓鞘与 COVID-19 感染的关联:一项更新的系统综述。
J Neurol. 2022 Feb;269(2):541-576. doi: 10.1007/s00415-021-10752-x. Epub 2021 Aug 12.
4
Neurological Manifestations and their Correlated Factors in COVID-19 Patients; a Cross-Sectional Study.COVID-19患者的神经学表现及其相关因素;一项横断面研究。
Arch Acad Emerg Med. 2021 Apr 27;9(1):e34. doi: 10.22037/aaem.v9i1.1210. eCollection 2021.
5
Update on brain MRI for the diagnosis and follow-up of MS patients.脑 MRI 在多发性硬化症患者诊断和随访中的应用进展。
Presse Med. 2021 Jun;50(2):104067. doi: 10.1016/j.lpm.2021.104067. Epub 2021 May 11.
6
Demyelination as a result of an immune response in patients with COVID-19.COVID-19 患者因免疫反应导致的脱髓鞘。
Acta Neurol Belg. 2021 Aug;121(4):859-866. doi: 10.1007/s13760-021-01691-5. Epub 2021 May 2.
7
Cellular immunology of relapsing multiple sclerosis: interactions, checks, and balances.复发型多发性硬化的细胞免疫学:相互作用、检查和平衡。
Lancet Neurol. 2021 Jun;20(6):470-483. doi: 10.1016/S1474-4422(21)00063-6. Epub 2021 Apr 27.
8
The Impact of SARS-CoV-2 Infection on the Development of Neurodegeneration in Multiple Sclerosis.严重急性呼吸综合征冠状病毒 2 感染对多发性硬化症中神经退行性变发展的影响。
Int J Mol Sci. 2021 Feb 11;22(4):1804. doi: 10.3390/ijms22041804.
9
Neuroinvasion of SARS-CoV-2 in human and mouse brain.新冠病毒在人和鼠脑内的神经入侵。
J Exp Med. 2021 Mar 1;218(3). doi: 10.1084/jem.20202135.
10
Could Sars-Cov2 affect MS progression?新冠病毒会影响多发性硬化症的进展吗?
Mult Scler Relat Disord. 2020 Nov;46:102540. doi: 10.1016/j.msard.2020.102540. Epub 2020 Sep 29.

新型冠状病毒肺炎及其对多发性硬化临床-放射学病程的影响:一项病例对照研究。

COVID-19 and its implications on the clinico-radiological course of multiple sclerosis: A case-control study.

机构信息

Department of Neurology, School of Medicine, AJA University of Medical Sciences, Tehran, Iran.

Multiple Sclerosis Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran.

出版信息

Med Clin (Barc). 2023 Mar 10;160(5):187-192. doi: 10.1016/j.medcli.2022.06.020. Epub 2022 Aug 10.

DOI:10.1016/j.medcli.2022.06.020
PMID:36089420
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9364744/
Abstract

BACKGROUND

Multiple sclerosis (MS) is an immune-mediated disease that has been related to several risk factors such as various viral infections. We carried out this study in order to establish a relationship between COVID-19 infection and MS severity.

METHODS

In a case-control study, we recruited patients with relapsing-remitting multiple sclerosis (RRMS). Patients were divided into two groups based on positive COVID-19 PCR at the end of the enrollment phase. Each patient was prospectively followed for 12 months. Demographical, clinical, and past medical history were collected during routine clinical practice. Assessments were performed every six months; MRI was performed at enrollment and 12 months later.

RESULTS

Three hundred and sixty-two patients participated in this study. MS patients with COVID-19 infection had significantly higher increases in the number of MRI lesions (p: 0.019, OR(CI): 6.37(1.54-26.34)) and EDSS scores (p: 0.017), but no difference was found in total annual relapses or relapse rates. COVID-19 infections were positively correlated with EDSS progression (p: 0.02) and the number of new MRI lesions (p: 0.004) and predicted the likelihood of the number of new MRI lesions by an odds of 5.92 (p: 0.018).

CONCLUSION

COVID-19 may lead to higher disability scores in the RRMS population and is associated with developing new Gd-enhancing lesions in MRI imaging. However, no difference was observed between the groups regarding the number of relapses during follow-up.

摘要

背景

多发性硬化症(MS)是一种免疫介导的疾病,与多种危险因素有关,如各种病毒感染。我们进行这项研究是为了确定 COVID-19 感染与 MS 严重程度之间的关系。

方法

在一项病例对照研究中,我们招募了复发缓解型多发性硬化症(RRMS)患者。根据在入组阶段末 COVID-19 PCR 阳性结果,将患者分为两组。每位患者前瞻性随访 12 个月。在常规临床实践中收集人口统计学、临床和既往病史。每 6 个月进行评估;在入组时和 12 个月后进行 MRI 检查。

结果

共有 362 名患者参与了这项研究。COVID-19 感染的 MS 患者的 MRI 病变数量(p:0.019,OR(CI):6.37(1.54-26.34))和 EDSS 评分(p:0.017)显著增加,但总年度复发率或复发率无差异。COVID-19 感染与 EDSS 进展(p:0.02)和新 MRI 病变数量(p:0.004)呈正相关,新 MRI 病变数量的可能性比为 5.92(p:0.018)。

结论

COVID-19 可能导致 RRMS 人群的残疾评分更高,并与 MRI 成像中新的 Gd 增强病变的发展相关。然而,在随访期间,两组之间的复发次数没有差异。